Clinical stage biopharmaceutical company Pulmatrix Inc (NASDAQ: PULM) announced on Monday that Rick Batycky PhD has been appointed to its board of directors.
With more than two decades of experience with biotech start-ups from founding to acquisition across an array of platforms and disease states with significant expertise in inhaled drug development, Dr Batycky currently serves as CEO at Nocion Therapeutics.
Dr Batycky was the chief scientific officer and a founder of Civitas Therapeutics, which was acquired by Acorda. Whilst at Acorda, Dr Batycky was chief technology officer .
Previously, Dr Batycky was chief scientific officer and senior VP of R&D at Pulmatrix and held prior positions at Alkermes and Advanced Inhalation Research.
Pulmatrix is developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE technology. Its proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis (ABPA) and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease (COPD).
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business